NASDAQ:TTNP Titan Pharmaceuticals 5/15/2024 Earnings Report $5.92 +1.14 (+23.70%) Closing price 10/1/2025Extended Trading$5.92 0.00 (0.00%) As of 10/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Titan Pharmaceuticals EPS ResultsActual EPS-$1.24Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATitan Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATitan Pharmaceuticals Announcement DetailsQuarterDate5/15/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Titan Pharmaceuticals Earnings HeadlinesTitan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Significant Drop in Short InterestOctober 7 at 2:40 AM | americanbankingnews.comTitan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan CorporationOctober 3, 2025 | globenewswire.comForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet.October 7 at 2:00 AM | Behind the Markets (Ad)Titan Pharmaceuticals Approves Merger with Black TitanAugust 26, 2025 | msn.comTITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNPAugust 5, 2025 | businesswire.comURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)July 29, 2025 | globenewswire.comSee More Titan Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Titan Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Titan Pharmaceuticals and other key companies, straight to your email. Email Address About Titan PharmaceuticalsTitan Pharmaceuticals (NASDAQ:TTNP) is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics based on its ProNeura long‐term, continuous drug delivery platform. Headquartered in South San Francisco, California, the company seeks to enhance patient outcomes through sustained‐release implants designed to deliver medication over extended periods. Titan’s platform is engineered to maintain consistent drug levels while reducing dosing frequency, with the goal of improving compliance and minimizing side effects often associated with conventional dosing schedules. The company’s lead product, Probuphine®, is a buprenorphine implant approved by the U.S. Food and Drug Administration in 2016 for maintenance treatment of opioid dependence. Probuphine delivers six months of continuous buprenorphine therapy via a small subdermal implant, offering an alternative to daily oral dosages. Titan originally commercialized Probuphine through a partnership with a specialty pharmaceutical company, and it continues to explore strategic collaborations to expand patient access within the United States and potential markets overseas. In addition to its marketed product, Titan maintains a pipeline of development programs aimed at addressing central nervous system disorders. Research efforts include next‐generation implants for migraine prophylaxis and psychiatric indications such as schizophrenia. The company’s leadership team, led by President and Chief Executive Officer Sunil Bhonsle, combines expertise in drug delivery technology and biopharmaceutical development. Titan Pharmaceuticals remains committed to advancing its ProNeura platform to bring long‐acting implant therapies to patients with chronic and complex conditions.View Titan Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
